Literature DB >> 19500440

A short history of health technology assessment in Germany.

Matthias Perleth1, Bernhard Gibis, Britta Göhlen.   

Abstract

OBJECTIVES: To provide an overview of the development of health technology assessment (HTA) in Germany since the 1990s.
METHODS: Analysis of key documents (e.g. literature, laws, and other official documentation) and personal experiences.
RESULTS: Health technology assessment (HTA) entered the political agenda in Germany only in the mid-1990s, basically as the result of a top-down approach toward more efficiency in health care, but with a strong impetus of an evidence-based medicine movement. Accordingly, HTA became part of several healthcare reform laws since 1997, which led to the establishment of the Federal Joint Committee (G-BA) and the Institute for Quality and Efficiency in Health Care (IQWiG) in 2004. This tandem construction aims at using evidence in decision-making processes for coverage and other decisions.
CONCLUSIONS: These developments have led to a considerable impact of HTA in Germany. In addition, a broad spectrum of activities at universities and in other organizations, such as the German Institute for Medical Documentation and Information (DIMDI), can be observed that contribute to both teaching and research in HTA. German researchers in the field of HTA are actively involved in international projects, such as EUNetHTA, and contribute to scientific conferences and journals.

Mesh:

Year:  2009        PMID: 19500440     DOI: 10.1017/S0266462309090515

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  10 in total

1.  Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.

Authors:  Tania Stafinski; Devidas Menon; Caroline Davis; Christopher McCabe
Journal:  Clinicoecon Outcomes Res       Date:  2011-08-30

2.  Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor.

Authors:  Pepijn Vemer; Maureen P M H Rutten-van Mölken
Journal:  Eur J Health Econ       Date:  2010-05-30

3.  "We noticed that suddenly the country has become full of MRI". Policy makers' views on diffusion and use of health technologies in Iran.

Authors:  Mohammad Palesh; Carol Tishelman; Sten Fredrikson; Hamidreza Jamshidi; Göran Tomson; Azita Emami
Journal:  Health Res Policy Syst       Date:  2010-04-06

4.  Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.

Authors:  Christine Blome; Matthias Augustin; Hidayet Metin; David Lohrberg
Journal:  Eur J Health Econ       Date:  2016-02-02

5.  The Role of decision-analytic modelling in German health technology assessments.

Authors:  Alexander Kuhlmann; Marina Treskova; Sebastian Braun; J-Matthias Graf von der Schulenburg
Journal:  Health Econ Rev       Date:  2015-02-19

6.  Management of Medical Technology under the New Medical Policy Background in China.

Authors:  Suo-Wei Wu; Tong Chen; Ming Wu; Qi Pan; Yong Xuan; Liang-Yu Wei; Qin Wang; Chao Li; Jing-Chen Song
Journal:  Chin Med J (Engl)       Date:  2016-11-20       Impact factor: 2.628

7.  Evidence-based decision-making for diagnostic and therapeutic methods: the changing landscape of assessment approaches in Germany.

Authors:  Britta Olberg; Sabine Fuchs; Katja Matthias; Alexandra Nolting; Matthias Perleth; Reinhard Busse
Journal:  Health Res Policy Syst       Date:  2017-10-17

8.  Establishment of a Quantitative Medical Technology Evaluation System and Indicators within Medical Institutions.

Authors:  Suo-Wei Wu; Tong Chen; Qi Pan; Liang-Yu Wei; Qin Wang; Chao Li; Jing-Chen Song; Ji Luo
Journal:  Chin Med J (Engl)       Date:  2018-06-05       Impact factor: 2.628

9.  Health technology assessment: the process in Brazil.

Authors:  Fernanda Lessa; Marcos Bosi Ferraz
Journal:  Rev Panam Salud Publica       Date:  2017-06-08

10.  Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives.

Authors:  Eline van Overbeeke; Valérie Forrester; Steven Simoens; Isabelle Huys
Journal:  Patient       Date:  2021-01       Impact factor: 3.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.